A preliminary investigation on the efficacy of N -acetyl cysteine for mania or hypomania
The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Objective: Oxidative imbalance has emerged as a treatment target in bipolar disorder. As very limited data are available on the clinical use of antioxidants for mania, we report here results from a post hoc and exploratory subgroup analysis of a randomized, placebo-controlled trial of N-acetyl cysteine (NAC). Methods: This was a placebo-controlled, randomized, clinical trial assessing the effect of NAC over 24 weeks in mania or hypomania. Symptomatic and functional outcomes were collected over the study period. Results: Fifteen participants were available for this report; two participants in each group failed to complete all assessments. Within-group analyses pointed to an improvement in the NAC group on manic symptoms and worsening in the placebo group on depressive symptoms at endpoint. Conclusions: Although the sample size was small, these results indicated within-group efficacy for this glutathione precursor as compared to placebo. Future trials specifically designed to demonstrate the efficacy of NAC in mania are needed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There are four placebo‐controlled trials that investigated divalproex (level 4),432 N‐acetylcysteine (level 4),433 and quetiapine (level 4)434, 435; and one open‐label study of risperidone (level 4)436 in acute hypomania.”
Citations
Cites
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962 · cited 3×
“NAC: N-acetyl cysteine; YMRS: Young Mania Rating Scale; MADRS: Montgomery–Asberg Depression Rating Scale; GAF: Global Assessment of Functioning; BDRS: Bipolar Depression Rating Scale; LIFE-RIFT: Longitudinal Interval Follow-up Evaluation – Range of Impairment Functioning Tool; SLICE-LIFE: Streamlined Longitudinal Inte…”
MethodJournal of Clinical Psychiatry
(2018) · Journal of Clinical Psychiatry · doi:10.5505/kpd · Cited by 13,651
A Rating Scale for Mania: Reliability, Validity and Sensitivity
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.5.429 · Cited by 8,744 · cited 3×
“NAC: N-acetyl cysteine; YMRS: Young Mania Rating Scale; MADRS: Montgomery–Asberg Depression Rating Scale; GAF: Global Assessment of Functioning; BDRS: Bipolar Depression Rating Scale; LIFE-RIFT: Longitudinal Interval Follow-up Evaluation – Range of Impairment Functioning Tool; SLICE-LIFE: Streamlined Longitudinal Inte…”
Method(1993) · PubMed · Cited by 1,900
Keller, M. B. (1987) · Archives of General Psychiatry · doi:10.1001/archpsyc.1987.01800180050009 · Cited by 1,643 · cited 4×
“…Evaluation for the Longitudinal Interval Follow-up Evaluation (SLICE-LIFE), the Longitudinal Interval Follow-up Evaluation – Range of Impairment Functioning Tool (LIFE-RIFT; Keller et al., 1987) and the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q; Endicott et al., 1993).”
MethodInfluentialBerk, M., Kapczinski, F., Andreazza, A. C., Dean, O. M., Giorlando, F., Maes, M., Yücel, M., Gama, C. S., Dodd, S., Dean, B., et al. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.10.001 · Cited by 1,178
Self-citationMorosini, P. L., Magliano, L., Brambilla, L., Ugolini, S., & Pioli, R. (2000) · PubMed · Cited by 1,168
Morosini, P. L., Magliano, L., Brambilla, L., Ugolini, S., & Pioli, R. (2000) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2000.101004323.x · Cited by 1,097 · cited 4×
“NAC: N-acetyl cysteine; YMRS: Young Mania Rating Scale; MADRS: Montgomery–Asberg Depression Rating Scale; GAF: Global Assessment of Functioning; BDRS: Bipolar Depression Rating Scale; LIFE-RIFT: Longitudinal Interval Follow-up Evaluation – Range of Impairment Functioning Tool; SLICE-LIFE: Streamlined Longitudinal Inte…”
MethodInfluentialOxidative stress in psychiatric disorders: evidence base and therapeutic implications
Ng, F., Berk, M., Dean, O., & Bush, A. I. (2008) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145707008401 · Cited by 1,069 · cited 2×
“Clinical and animal studies demonstrate that mood stabilizers improve oxidative stress parameters (Ng et al., 2008; Frey et al., 2006; Machado-Vieira et al., 2010).”
BackgroundSelf-citationJones, S. H., Thornicroft, G., Coffey, M., & Dunn, G. (1995) · British Journal of Psychiatry · doi:10.1192/bjp.166.5.654 · Cited by 1,015 · cited 4×
“NAC: N-acetyl cysteine; YMRS: Young Mania Rating Scale; MADRS: Montgomery–Asberg Depression Rating Scale; GAF: Global Assessment of Functioning; BDRS: Bipolar Depression Rating Scale; LIFE-RIFT: Longitudinal Interval Follow-up Evaluation – Range of Impairment Functioning Tool; SLICE-LIFE: Streamlined Longitudinal Inte…”
MethodInfluentialSpearing, M. K., Post, R. M., Leverich, G. S., Brandt, D., & Nolen, W. (1997) · Psychiatry Research · doi:10.1016/s0165-1781(97)00123-6 · Cited by 978 · cited 1×
“The Clinical Global Impression (CGI; Spearing et al., 1997) was obtained as a measure of overall illness severity.”
MethodPostpartum mood disorders: diagnosis and treatment guidelines.
Nonacs, R. M., & Cohen, L. S. (1998) · PubMed · Cited by 637
Yatham, L. N., Kennedy, S. H., Schaffer, A., Parikh, S. V., Beaulieu, S., O'Donovan, C., MacQueen, G., McIntyre, R. S., Sharma, V., Ravindran, A., et al. (2009) · Bipolar Disorders · doi:10.1111/j.1399-5618.2009.00672.x · Cited by 570 · cited 1×
“There is current interest in investigating interventions with novel mechanisms of action in bipolar disorder (Yatham et al., 2009).”
BackgroundSelf-citationBerk, M., Copolov, D. L., Dean, O., Lu, K., Jeavons, S., Schapkaitz, I., Anderson-Hunt, M., & Bush, A. I. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.04.022 · Cited by 500
Self-citationN-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action
Dean, O., Giorlando, F., & Berk, M. (2011) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.100057 · Cited by 494
Self-citationThe promise of N-acetylcysteine in neuropsychiatry
Berk, M., Malhi, G. S., Gray, L. J., & Dean, O. M. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.01.001 · Cited by 434
Self-citationN -acetylcysteine for antioxidant therapy: pharmacology and clinical utility
Dodd, S., Dean, O., Copolov, D. L., Malhi, G. S., & Berk, M. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14728220802517901 · Cited by 413 · cited 2×
“On the whole, NAC has proven to be an interesting add-on drug in psychiatric disorders (Berk et al., 2011a; Dean et al., 2011a, 2012), both due to its benign profile of side effects (Dodd et al., 2008, 2009) and growing evidence regarding its efficacy (Berk et al., 2000, 2008a).”
BackgroundSelf-citationN-Acetylcysteine reverses cocaine-induced metaplasticity
Moussawi, K., Pacchioni, A., Moran, M., Olive, M. F., Gass, J. T., Lavin, A., & Kalivas, P. W. (2009) · Nature Neuroscience · doi:10.1038/nn.2250 · Cited by 399 · cited 2×
“Australian & New Zealand Journal of Psychiatry, 47(6) glutamate-modulating properties (Moussawi et al., 2009) and, given that increased glutamatergic neurotransmission has been found in bipolar disorder (Yildiz-Yesiloglu and Ankerst, 2006), this may represent an additional therapeutic pathway.”
BackgroundSerum S100B and antioxidant enzymes in bipolar patients
Andreazza, A. C., Cassini, C., Rosa, A. R., Leite, M. C., de Almeida, L. M. V., Nardin, P., Cunha, A. B. N., Ceresér, K. M., Santin, A., Gottfried, C., et al. (2007) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2006.07.013 · Cited by 309 · cited 1×
“Adding to this, disturbances in antioxidant enzymes have also been found during mania (Andreazza et al., 2007).”
BackgroundYildiz-Yesiloglu, A., & Ankerst, D. P. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.03.012 · Cited by 253 · cited 2×
“Australian & New Zealand Journal of Psychiatry, 47(6) glutamate-modulating properties (Moussawi et al., 2009) and, given that increased glutamatergic neurotransmission has been found in bipolar disorder (Yildiz-Yesiloglu and Ankerst, 2006), this may represent an additional therapeutic pathway.”
BackgroundPeripheral biomarkers and illness activity in bipolar disorder
Kapczinski, F., Dal-Pizzol, F., Teixeira, A. L., Magalhaes, P. V. S., Kauer-Sant’Anna, M., Klamt, F., Moreira, J. C. F., Augusto de Bittencourt Pasquali, M., Fries, G. R., Quevedo, J., et al. (2011) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2010.05.015 · Cited by 236 · cited 1×
“Animal and clinical studies converge to suggest that acute manic episodes are especially associated with oxidative damage (Frey et al., 2006, 2007; Kapczinski et al., 2011).”
BackgroundGlutathione: a novel treatment target in psychiatry
Berk, M., Ng, F., Dean, O., Dodd, S., & Bush, A. I. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.05.001 · Cited by 183
Self-citationBerk, M., Dean, O., Cotton, S. M., Gama, C. S., Kapczinski, F., Fernandes, B. S., Kohlmann, K., Jeavons, S., Hewitt, K., Allwang, C., et al. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.06.005 · Cited by 181
Self-citationThe Bipolar Depression Rating Scale (BDRS): its development, validation and utility
Berk, M., Malhi, G. S., Cahill, C., Carman, A. C., Hadzi‐Pavlovic, D., Hawkins, M. T., Tohen, M., & Mitchell, P. B. (2007) · Bipolar Disorders · doi:10.1111/j.1399-5618.2007.00536.x · Cited by 154 · cited 1×
“Interviewers assessed mood using the Bipolar Depression Rating Scale (BDRS; Berk et al., 2004, 2007), the Montgomery–Asberg Depression Rating Scale (MADRS; Montgomery and Asberg, 1979), and the Young Mania Rating Scale (YMRS; Young et al., 1978).”
MethodSelf-citationMachado-Vieira, R., Soares, J. C., Lara, D. R., Luckenbaugh, D. A., Busnello, J. V., Marca, G., Cunha, A., Souza, D. O., Zarate, C. A., & Kapczinski, F. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0806 · Cited by 132 · cited 2×
“, 2010) and (with the possible exception of allopurinol (Machado-Vieira et al., 2008)) clinical trials of antioxidants for mania are largely lacking.”
BackgroundMediators of allostasis and systemic toxicity in bipolar disorder
Grande, I., Magalhães, P. V. D. S., Kunz, M., Vieta, E., & Kapczinski, F. P. (2011) · Physiology & Behavior · doi:10.1016/j.physbeh.2011.10.029 · Cited by 131 · cited 1×
“Oxidative imbalance has been shown to be pervasive in bipolar disorder (Berk et al., 2011b; Grande et al., 2012; Magalhães et al., 2012b, 2012c).”
BackgroundIncreased oxidative stress and DNA damage in bipolar disorder: A twin-case report
Frey, B. N., Andreazza, A. C., Kunz, M., Gomes, F. A., Quevedo, J., Salvador, M., Gonçalves, C. A., & Kapczinski, F. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.06.011 · Cited by 120
N-acetylcysteine for major depressive episodes in bipolar disorder
Magalhães, P. V., Dean, O. M., Bush, A. I., Copolov, D. L., Malhi, G. S., Kohlmann, K., Jeavons, S., Schapkaitz, I., Anderson-Hunt, M., & Berk, M. (2011) · Revista Brasileira de Psiquiatria · doi:10.1590/s1516-44462011000400011 · Cited by 114 · cited 1×
“As previously reported, add-on NAC was effective for bipolar disorder in a naturalistic, randomized, placebo-controlled trial with patients in the different phases of the disorder (Berk et al., 2008a; Magalhães et al., 2011a, 2012b).”
MethodSelf-citationFrey, B. N., Martins, M. R., Petronilho, F. C., Dal‐Pizzol, F., Quevedo, J., & Kapczinski, F. (2006) · Bipolar Disorders · doi:10.1111/j.1399-5618.2006.00318.x · Cited by 109 · cited 2×
“Animal and clinical studies converge to suggest that acute manic episodes are especially associated with oxidative damage (Frey et al., 2006, 2007; Kapczinski et al., 2011).”
BackgroundMagalhães, P. V., Dean, O. M., Bush, A. I., Copolov, D. L., Malhi, G. S., Kohlmann, K., Jeavons, S., Schapkaitz, I., Anderson-Hunt, M., & Berk, M. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2010.08.001 · Cited by 101 · cited 1×
“As previously reported, add-on NAC was effective for bipolar disorder in a naturalistic, randomized, placebo-controlled trial with patients in the different phases of the disorder (Berk et al., 2008a; Magalhães et al., 2011a, 2012b).”
MethodSelf-citationDean, O., den Buuse, M., Bush, A. I., Copolov, D. L., Ng, F., Dodd, S., & Berk, M. (2009) · Current Medicinal Chemistry · doi:10.2174/092986709788803060 · Cited by 101 · cited 1×
“With these new findings, there is growing interest in developing new interventions that directly target oxidative biology in bipolar disorder (Dean et al., 2009; Ng et al., 2008).”
BackgroundSelf-citationBerk, M., Dean, O. M., Cotton, S. M., Gama, C. S., Kapczinski, F., Fernandes, B., Kohlmann, K., Jeavons, S., Hewitt, K., Moss, K., et al. (2012) · BMC Medicine · doi:10.1186/1741-7015-10-91 · Cited by 96 · cited 1×
“Although there is hope that NAC may prove to be an agent able to halt neuroprogression, at this point there is insufficient clinical evidence (Berk et al., 2012).”
BackgroundSelf-citationDean, O. M., van den Buuse, M., Berk, M., Copolov, D. L., Mavros, C., & Bush, A. I. (2011) · Neuroscience Letters · doi:10.1016/j.neulet.2011.05.027 · Cited by 92
Self-citationThe empirical redefinition of the psychometric criteria for remission in bipolar disorder
Berk, M., Ng, F., Wang, W. V., Calabrese, J. R., Mitchell, P. B., Malhi, G. S., & Tohen, M. (2008) · Journal of Affective Disorders · doi:10.1016/j.jad.2007.06.011 · Cited by 85
Self-citationHarvey, B. H., Joubert, C., du Preez, J. L., & Berk, M. (2008) · Neurochemical Research · doi:10.1007/s11064-007-9466-y · Cited by 80 · cited 1×
“This would concur with preclinical data showing that there needs to be increasing oxidative stress as a substrate for NAC to have an effect (Harvey et al., 2008).”
BackgroundSelf-citationMagalhães, P. V. S., Jansen, K., Pinheiro, R. T., Colpo, G. D., da Motta, L. L., Klamt, F., da Silva, R. A., & Kapczinski, F. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001532 · Cited by 75 · cited 3×
“There is also a suggestion from this same clinical trial (Magalhães et al., 2012a) that NAC is especially effective in later stages of bipolar disorder.”
BackgroundMethodResultThe Specificity of Platelet Glutamate Receptor Supersensitivity in Psychotic Disorders
Berk, M., Plein, H., & Belsham, B. (2000) · Life Sciences · doi:10.1016/s0024-3205(00)80002-8 · Cited by 75 · cited 1×
“On the whole, NAC has proven to be an interesting add-on drug in psychiatric disorders (Berk et al., 2011a; Dean et al., 2011a, 2012), both due to its benign profile of side effects (Dodd et al., 2008, 2009) and growing evidence regarding its efficacy (Berk et al., 2000, 2008a).”
BackgroundSelf-citationNew Therapeutic Targets for Mood Disorders
Machado-Vieira, R., Salvadore, G., DiazGranados, N., Ibrahim, L., Latov, D., Wheeler-Castillo, C., Baumann, J., Henter, I. D., & Zarate, C. A. (2010) · The Scientific World JOURNAL · doi:10.1100/tsw.2010.65 · Cited by 63 · cited 3×
“Clinical and animal studies demonstrate that mood stabilizers improve oxidative stress parameters (Ng et al., 2008; Frey et al., 2006; Machado-Vieira et al., 2010).”
BackgroundChoy, K. H. C., Dean, O., Berk, M., Bush, A. I., & van den Buuse, M. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.09.035 · Cited by 62 · cited 1×
“Email: mikebe@barwonhealth.org.au Australian & New Zealand Journal of Psychiatry, 47(6) imbalance (Berk et al., 2008b; Choy et al., 2010; Dean et al., 2011a, 2011b).”
BackgroundSelf-citationScale matters: the need for a Bipolar Depression Rating Scale (BDRS)
Berk, M., Malhi, G. S., Mitchell, P. B., Cahill, C. M., Carman, A. C., Hadzi‐Pavlovic, D., Hawkins, M. T., & Tohen, M. (2004) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2004.00412.x · Cited by 59 · cited 1×
“Interviewers assessed mood using the Bipolar Depression Rating Scale (BDRS; Berk et al., 2004, 2007), the Montgomery–Asberg Depression Rating Scale (MADRS; Montgomery and Asberg, 1979), and the Young Mania Rating Scale (YMRS; Young et al., 1978).”
MethodSelf-citationSystemic illness moderates the impact of N-acetyl cysteine in bipolar disorder
Magalhães, P. V., Dean, O. M., Bush, A. I., Copolov, D. L., Weisinger, D., Malhi, G. S., Kohlmann, K., Jeavons, S., Schapkaitz, I., Anderson-Hunt, M., et al. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2011.11.011 · Cited by 28 · cited 3×
“There is also a suggestion from this same clinical trial (Magalhães et al., 2012a) that NAC is especially effective in later stages of bipolar disorder.”
BackgroundMethodResultSelf-citationMarcadores periféricos e a fisiopatologia do transtorno bipolar
Magalhães, P. V. D. S., Fries, G. R., & Kapczinski, F. P. (2012) · Archives of Clinical Psychiatry (São Paulo) · doi:10.1590/s0101-60832012000200004 · Cited by 26 · cited 3×
“There is also a suggestion from this same clinical trial (Magalhães et al., 2012a) that NAC is especially effective in later stages of bipolar disorder.”
BackgroundMethodResultTranslating the Rosetta Stone of N-Acetylcysteine
Dean, O. M., Bush, A. I., & Berk, M. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.04.001 · Cited by 25 · cited 1×
“On the whole, NAC has proven to be an interesting add-on drug in psychiatric disorders (Berk et al., 2011a; Dean et al., 2011a, 2012), both due to its benign profile of side effects (Dodd et al., 2008, 2009) and growing evidence regarding its efficacy (Berk et al., 2000, 2008a).”
BackgroundSelf-citation
Research works printed but not linked: 1
- Endicott J, 1993, Psychopharmacology Bulletin, 29, 321
Cited by
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852
Self-citationClinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review
Deepmala, Slattery, J., Kumar, N., Delhey, L., Berk, M., Dean, O., Spielholz, C., & Frye, R. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.04.015 · Cited by 463
Self-citationRaghu, G., Berk, M., Campochiaro, P. A., Jaeschke, H., Marenzi, G., Richeldi, L., Wen, F.-Q., Nicoletti, F., & Calverley, P. M. A. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666201230144109 · Cited by 280
“Data from various subgroup analyses further support the benefits of NAC in terms of symptom severity, functioning, response rate, symptom remission, and quality of life [155-158].”
Self-citationRosenblat, J., & McIntyre, R. (2017) · Brain Sciences · doi:10.3390/brainsci7110144 · Cited by 258
“This analysis revealed a greater improvement in symptoms of mania in the NAC group compared to placebo [118].”
ResultBiological hypotheses and biomarkers of bipolar disorder
Sigitova, E., Fišar, Z., Hroudová, J., Cikánková, T., & Raboch, J. (2017) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12476 · Cited by 235
“Antioxidants, such as N-acetylcysteine (NAC) seem to be beneficial in treatment of both major depressive episodes(236) and manic/hypomanic episodes.(237) NAC is a promising novel therapeutic option for BD and other neuropsychiatric disorders, because NAC targets glutamatergic transmission, glutathione, neurotrophins,…”
Background
Metadata
- Authors
- Vieira da Silva Magalhães, P., Dean, O. M., Bush, A. I., Copolov, D. L., Malhi, G. S., Kohlmann, K., Jeavons, S., Schapkaitz, I., Anderson-Hunt, M., & Berk, M.
- Affiliations
- National Institute for Translational Medicine, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
- Deakin University (AU)
- Monash University (AU)
- The University of Sydney (AU)
- School of Medicine, Deakin University, Geelong, Australia
- Venue
- Australian & New Zealand Journal of Psychiatry
- Publisher
- SAGE Publications
- Published
- 2013-03-14
- Volume
- 47
- Issue
- 6
- Pages
- 564-568
- ISSN
- 0004-8674 (ISSN-L)
- 1440-1614
- OpenAlex
- W2161212886
- Cited by
- 58
- References
- 43
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 1 · 2023: 2 · 2022: 4 · 2021: 3 · 2020: 5 · 2019: 3 · 2018: 8 · 2017: 4 · 2016: 10 · 2015: 7 · 2014: 3 · 2013: 3
- FWCI
- 5.42
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Australian & New Zealand Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Figshare (submittedVersion)
- Minerva Access (University of Melbourne) (submittedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- N-acetylcysteine, mania, hypomania, bipolar disorder, oxidative imbalance, antioxidants, glutathione precursor, manic symptoms, depressive symptoms, subgroup analysis
- MeSH terms
- Acetylcysteine, Adult, Antioxidants, Bipolar Disorder, Double-Blind Method, Female, Humans, Male, Middle Aged, Psychiatric Status Rating Scales
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.